Comparison of Intrathecal and Intravenous Analgesia in Patients Undergoing Liver Resection
Comparison of the Efficacy of Postoperative Analgesia by a Single Dose of Intrathecal Morphine and Intravenous Morphine: a Randomized Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Michał Grąt, MD, PhD
- Phone Number: +48225992541
- Email: michal.grat@gmail.com
Study Locations
-
-
Mazowieckie
-
Warsaw, Mazowieckie, Poland, 02-097
- Recruiting
- Department of General, Transplant and Liver Surgery, Medical University of Warsaw
-
Contact:
- Michał Grąt, M.D., Ph.D.
- Phone Number: +48225992545
- Email: hepaclin@wum.edu.pl
-
Sub-Investigator:
- Michał Grąt, M.D., Ph.D.
-
Principal Investigator:
- Wojciech Figiel, M.D.
-
Warsaw, Mazowieckie, Poland, 02-097
- Recruiting
- II Department of Anaesthesiology and Intensive Care, Medical University of Warsaw
-
Contact:
- Grzegorz Niewiński, MD, PhD
- Phone Number: +48225992367
- Email: grzegorzniewinski@wp.pl
-
Sub-Investigator:
- Marta Dec, MD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- liver resection
- liver malignancy
Exclusion Criteria:
- >3 points in American Society of Anesthesiology (ASA) scale
- contra-indications for intrathecal morphine administration
- chronic preoperative intake of analgetics
- a history of opioid dependency
- body mass index >45 kg/m2
- allergy to any analgetic drug administered in the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Intrathecal morphine
Intrathecal morphine (0,4 mg) immediately before operation
|
Single dose (0,4 mg) intrathecal morphine immediately before operation, patient-controlled analgesia with morphine (2 mg intravenously, a least 20 min interval) over first 24 postoperative hours and subcutaneous morphine (5 mg in case of numerical rating scale>4, at least 6 hour interval) over next two days in the postoperative period
|
|
Active Comparator: Intravenous morphine
Intravenous morphine (0,15 mg/kg body mass) immediately after the operation
|
Single dose of intravenous morphine (0,15 mg/kg body mass) immediately after the operation, patient controlled analgesia with morphine (2 mg intravenously, a least 20 min interval) over first 24 postoperative hours and subcutaneous morphine (5 mg in case of numerical rating scale>4, at least 6 hour interval) over next two days
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Severity of pain at rest
Time Frame: 3 days
|
Severity of pain assessed in numerical rating scale twice daily
|
3 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Severity of pain at coughing
Time Frame: 3 days
|
Severity of pain assessed in numerical rating scale twice daily
|
3 days
|
|
Morphine usage
Time Frame: 3 days
|
Total dose of morphine administered intravenously and subcutaneously
|
3 days
|
|
Time to mobilization
Time Frame: 90 days
|
Time to self-standing after the operation
|
90 days
|
|
Grade of sedation
Time Frame: 3 days
|
Richmond Agitation and Sedation Scale
|
3 days
|
|
Solid food tolerance
Time Frame: 90 days
|
Time to solid food intake
|
90 days
|
|
Duration of hospitalization
Time Frame: 90 days
|
Postoperative hospital stay
|
90 days
|
|
Postoperative complications
Time Frame: 90 days
|
Postoperative complications according to Clavien-Dindo classification
|
90 days
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Grzegorz Niewiński, MD, PhD, Medical University of Warsaw
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 1WB1/2018/1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.